The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 19)
Improved Biomarkers and Clinical Outcome Measures, 2017
Recent reports of "super-smelling powers" published in The Lancet Neurology has triggered the idea of a specific "musky" scent in the sebum, an oily skin secretion, of those with Parkinson's disease (PD), providing a novel basis for PD biomarker (tracks disease activity) research. Our customizable MouSensor technology allows creation of highly sensitive biosensors for specific odo...
LRRK2 Cohort Consortium, 2012
Parkinson's Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role this mutation plays in individuals that were exposed to environmental toxicants.
A novel feature of this work is the investigation of the effect of a second significant genetic cause of Parkinson's dise...
Researchers: Birgitt Schüle, MD
Rapid Response Innovation Awards, 2012
Orthostatic hypotension is a sudden drop in blood pressure (BP) when an individual changes position. Individuals with Parkinson's disease (PD) commonly suffer from orthostatic hypotension and low BP due to reduced levels of the neurotransmitter norepinephrine. Medications used to treat PD (such as levodopa) reduce norepinephrine levels, thus further reducing BP. Tyrosine is a ...
Researchers: Joanne DiFrancisco-Donoghue, PhD, RCEP
LRRK2 Cohort Working Group, 2012
Two groups have reported a possible association between carrying a LRRK2 mutation and non-skin cancers. In order to determine whether this finding is present in a larger group, or whether specific factors in those populations account for the higher rate of cancer, a larger study from more locations, and with a larger group of Parkinson's subjects and their family...
Researchers: Rachel Saunders-Pullman, MD, MPH, MS
MJFF Research Grant, 2011
Loss of dopamine-producing neurons in Parkinson's disease (PD) is accompanied by inflammation in surrounding support cells, called glial cells. This inflammatory state in glial cells leads to production of toxic substances that further damage neurons, leading to a viscous cycle of inflammatory damage that ultimately worsens the progression of the disease. New evidence in expe...
Researchers: Ronald Tjalkens, PhD